On July 22, 1994, Garret, Claude; Montier, Francois published a patent.HPLC of Formula: 81616-80-0 The title of the patent was Pharmaceutical compositions containing synergistic Nk1 and NK2 receptor antagonists. And the patent contained the following:
Pharmaceutical compositions containing synergistic Nk1 and NK2 receptor antagonists are used for the treatment of diseases caused by substance P and/or neurokinine A. I.v. injection of [imino-1-(methoxy-2-phenyl)-2-ethyl]-2-diphenyl-7,7-perhydroisoindolone-4-(3aR,7aR) (preparation given) and N-methyl[(phenyl-4-acetamido-4-piperidinyl)-4-(dichloro-3,4-phenyl)-2-butyl]benzamide (I) at 0.5mg/kg did not inhibit the capsaicin-induced bladder contractions in rats, while the combination of both decreased the contractions by 74%. A tablet contained [diphenyl-7,7-(methoxy-2-phenyl)-2-propionyl-(S)]-2-perhydroisoindolol-4-(3aS,4S, 7aS) 12.5, I 12.5, starch 83, silica 30, and Mg stearate 3 mg. The experimental process involved the reaction of (S)-2-(2-Methoxyphenyl)propanoic acid(cas: 81616-80-0).HPLC of Formula: 81616-80-0
The Article related to pharmaceutical synergism nk1 nk2 receptor antagonist, tablet synergism nk1 nk2 receptor antagonist, Pharmaceuticals: Formulation and Compounding and other aspects.HPLC of Formula: 81616-80-0
Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem